Quantification of Infant Motor Development to Predict Risk for Neurodevelopmental Disorders

项目摘要/摘要 在这个K23职业发展奖中，鲁朱塔·威尔逊博士将开发运动定量分析方面的培训 开发以帮助早期识别神经发育障碍(NDDS)。威尔逊博士的长期 目标是成为运动开发方面的领先临床医生和科学家，利用新的定量方法和 分析以确定运动障碍的机制、生物标记物和治疗方法 受这些损伤影响的发育期人群。通过这个K23的支持和丰富的 在加州大学洛杉矶分校的跨学科培训环境和资源方面，威尔逊博士的目标是实现以下目标 培训目标：(1)培养婴儿运动和发育的理论模型和评估方面的专业知识 轨迹，(2)获得最优统计方法的知识和纵向建模、信号处理的技能 处理和机器学习技术，以分析复杂的量化电机数据并开发 预测模型，(3)精通先进的临床研究设计和方法 实施，以及(4)将K23培训和结果转换为R01，利用运动风险标记来帮助 有针对性的运动干预的临床分层和监测发展结果。要实现这些目标 目标，威尔逊博士组建了一支模范的导师团队，其中包括她的主要导师詹姆斯博士 McCracken是一位儿童精神病学家，数十年来致力于研究儿童和儿童的发展 NDDS临床试验的设计和实施；共同导师，Grace Baranek博士，感官研究的领导者- NDDS出生第一年的运动和行为风险标记物；共同导师，David Elashoff博士， 对高维数据集和传感器监测数据有丰富知识的生物统计学；合作者 撰稿人威廉·凯泽博士、贝丝·史密斯博士、沙法利·杰斯特博士和苏珊·布克海默博士 信号处理和机器学习的分析技术，可穿戴传感器，高危婴儿研究，以及 分别对高危婴儿进行神经影像检查。运动障碍发生在一系列NDD和 在病程早期出现，但早期识别仍然是一个持续的挑战，因为缺乏 可以客观地识别这些早期运动障碍的量化指标。的首要目标是 拟议的纵向研究是：(1)利用经过验证的可穿戴传感器来得出以下定量测量结果 运动功能和识别NDDS高危婴儿(例如，有较大兄弟姐妹的婴儿)的运动障碍 患有自闭症谱系障碍[ASD])早在3个月大时，以及(2)检查它们之间的关系 运动障碍与自闭症症状以及社交、语言和认知方面的延迟有关。这 提案将促进新的跨诊断马达表型工具的开发，这些工具可用于 为一系列神经病学的临床筛查、临床风险分层和干预研究提供信息 精神错乱。这些目标直接涉及NICHD的研究优先事项；特别是“建立 智力和发育障碍症状的生物标记物和结果衡量标准的有效性。

Project Summary/Abstract In this K23 career development award, Dr. Rujuta Wilson will develop training in quantitative analysis of motor development to aid in early identification of neurodevelopmental disorders (NDDs). Dr. Wilson’s longer-term goal is to be a leading clinician-scientist in motor development, utilizing novel quantitative methods and analyses to identify mechanisms, biomarkers, and treatments of motor impairments across diverse developmental populations affected by these impairments. Through the support of this K23 and the enriched transdisciplinary training environment and resources at UCLA, Dr. Wilson aims to accomplish the following training goals: (1) develop expertise in theoretical models and assessment of infant motor and developmental trajectories, (2) acquire knowledge of optimal statistical methods and skills in longitudinal modeling, signal processing, and machine learning techniques to analyze complex quantitative motor data and develop prediction models, (3) develop proficiency in advanced methods of clinical research design and implementation, and (4) translate the K23 training and findings into an R01 utilizing motor risk markers to aid in clinical stratification and monitor developmental outcomes of a targeted motor intervention. To achieve these goals, Dr. Wilson has assembled an exemplary mentorship team, including her primary mentor, Dr. James McCracken, a child psychiatrist with decades of research dedicated to studying development in children and in design and conduct of clinical trials in NDDs; co-mentor, Dr. Grace Baranek, a leader in the study of sensory- motor and behavioral risk markers of NDDs in the first year of life; co-mentor, Dr. David Elashoff, a leader of biostatistics with extensive knowledge of high dimensional data sets and sensor monitoring data; collaborators and contributors, Drs. William Kaiser, Beth Smith, Shafali Jeste, and Susan Bookheimer, experts in advanced analytic techniques of signal processing and machine learning, wearable sensors, high risk infant studies, and neuroimaging methods in high risk infants, respectively. Motor impairments occur across an array of NDDs and emerge early in disease course, but early identification remains an ongoing challenge due to lack of quantitative measures that can objectively identify these early motor impairments. The overarching goal of the proposed longitudinal study is to (1) utilize a validated wearable sensor to derive quantitative measurements of motor function and identify motor impairments in infants at high risk for NDDs (e.g., infants with an older sibling with Autism Spectrum Disorder [ASD]) as early as 3 months of age, and (2) examine the relationship of these motor impairments to symptoms of ASD and to delays in social communication, language, and cognition. This proposal will facilitate the development of novel transdiagnostic motor phenotyping tools that can be utilized to inform clinical screening, clinical risk stratification, and intervention studies across a range of neurologic disorders. These aims directly address NICHD research priorities; in particular, “research establishing the validity of biomarkers and outcome measures for intellectual and developmental disability symptoms.”